MCID: MSL001
MIFTS: 65

Measles

Categories: Infectious diseases, Rare diseases, Smell/Taste diseases

Aliases & Classifications for Measles

Summaries for Measles

MedlinePlus : 43 Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella, is a completely different illness. Centers for Disease Control and Prevention

MalaCards based summary : Measles, also known as rubeola, is related to rubella and mumps, and has symptoms including fever, conjunctivitis and cough. An important gene associated with Measles is CD46 (CD46 Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Vitamin A and BCG vaccine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and t cells, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Measles virus, which is transmitted by contact with oronasal secretions, or semen of an infected person. The infection has symptom fever, has symptom cough, has symptom coryza, has symptom conjunctivitis, and has symptom maculopapular, erythematous rash.

CDC : 3 Measles starts with fever, runny nose, cough, red eyes, and sore throat. It’s followed by a rash that spreads over the body. Measles virus is highly contagious virus and spreads through the air through coughing and sneezing. Make sure you and your child are protected with measles, mumps, and rubella (MMR) vaccine.

Wikipedia : 76 Measles is a highly contagious infectious disease caused by the measles virus. Symptoms usually develop... more...

Related Diseases for Measles

Diseases related to Measles via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 rubella 33.7 DDX58 IFNAR2 IL4
2 mumps 32.1 CD46 IFNAR2 IFNG IL2 STAT1
3 encephalitis 31.0 CD209 DDX58 TLR3
4 stomatitis 30.4 ADAR DDX58 EIF2AK2
5 tetanus 30.3 IFNG IL2 IL4
6 influenza 30.0 DDX58 EIF2AK2 IFIH1 IFNA1 IFNB1 IFNG
7 japanese encephalitis 29.9 CD209 DDX58 IFNB1 STAT1 TLR3
8 human immunodeficiency virus infectious disease 29.9 IFNA1 IFNG IL2
9 demyelinating disease 29.9 IFNA1 IFNB1 IFNG
10 severe acute respiratory syndrome 29.7 CD209 IFNA1 IFNB1 IFNG STAT1
11 newcastle disease 29.7 DDX58 IFNA1 IFNB1
12 dengue virus 29.6 CD209 DDX58 IFIH1
13 variola major 29.6 IFNG IL2 TLR3
14 multiple sclerosis 29.6 IFNA1 IFNB1 IFNG IL2 IL4 STAT1
15 herpes simplex 29.6 CD209 DDX58 EIF2AK2 IFIH1 IFNA1 IFNB1
16 mouth disease 29.5 IFNA1 IFNG STAT1 TLR3
17 hepatitis c virus 29.5 DDX58 EIF2AK2 IFIH1 IFNG
18 viral infectious disease 29.5 CD209 DDX58 EIF2AK2 IFIH1 IFNA1 IFNB1
19 mycoplasma pneumoniae pneumonia 29.5 IFNG IL4 TLR2
20 pulmonary tuberculosis 29.4 IFNG IL2 IL4 TLR2
21 west nile virus 29.4 CD209 DDX58 IFIH1 IFNA1 TLR3
22 vaccinia 29.4 EIF2AK2 IFNA1 IFNB1 IL2
23 tonsillitis 29.4 IFNG IL2 IL4
24 dermatitis, atopic 29.3 IFNG IL2 IL4 TLR2
25 virus associated hemophagocytic syndrome 29.3 IL2 IL4
26 acquired immunodeficiency syndrome 29.3 IFNA1 IFNG IL2
27 toxic shock syndrome 29.2 IFNG IL2 IL4 TLR2
28 human immunodeficiency virus type 1 29.2 ADAR CD209 IFNG IL2 STAT1 TLR3
29 inflammatory bowel disease 29.2 IFNG IL2 IL4 STAT1 TLR2
30 malaria 29.2 FCGR2B IFNG IL2 IL4 TLR2
31 schistosomiasis 29.1 IFNG IL2 IL4
32 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.1 CD209 IFNG IL2 IL4
33 hepatitis c 29.0 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 IFNG
34 cutaneous t cell lymphoma 29.0 IFNA1 IFNG IL2 IL4
35 systemic lupus erythematosus 28.2 FCGR2B IFNA1 IFNB1 IFNG IL2 IL4
36 panencephalitis, subacute sclerosing 12.2
37 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 12.1
38 congenital rubella 11.5
39 acute disseminated encephalomyelitis 11.5
40 croup 11.3
41 striatonigral degeneration, infantile 11.3
42 acute hemorrhagic leukoencephalitis 11.0
43 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0
44 immunodeficiency 45 11.0
45 microcephaly 11.0
46 immune-mediated encephalomyelitis 11.0
47 postinfectious encephalomyelitis 11.0
48 pertussis 10.5
49 chickenpox 10.4
50 diphtheria 10.4

Graphical network of the top 20 diseases related to Measles:



Diseases related to Measles

Symptoms & Phenotypes for Measles

Symptoms:

12
  • fever
  • conjunctivitis
  • cough
  • coryza
  • maculopapular

UMLS symptoms related to Measles:


fever, pruritus, exanthema, koplik spots

MGI Mouse Phenotypes related to Measles:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 ADAR DDX58 DHX58 EIF2AK2 FCGR2B IFIH1
2 cellular MP:0005384 10.17 ADAR DDX58 DHX58 EIF2AK2 FCGR2B IFIH1
3 homeostasis/metabolism MP:0005376 10.13 ADAR DDX58 DHX58 FCGR2B IFIH1 IFNAR2
4 immune system MP:0005387 10.13 ADAR DDX58 DHX58 EIF2AK2 FCGR2B IFIH1
5 digestive/alimentary MP:0005381 9.95 DDX58 FCGR2B IFNG IL2 IL4 STAT1
6 liver/biliary system MP:0005370 9.81 ADAR DDX58 FCGR2B IFIH1 IFNG IL2
7 mortality/aging MP:0010768 9.77 ADAR DDX58 DHX58 EIF2AK2 FCGR2B IFIH1
8 neoplasm MP:0002006 9.28 DDX58 EIF2AK2 IFNAR2 IFNB1 IFNG IL2

Drugs & Therapeutics for Measles

Drugs for Measles (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 11103-57-4, 68-26-8 445354
2
BCG vaccine Investigational Phase 4,Phase 2
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Liver Extracts Phase 4,Phase 1
8 Micronutrients Phase 4,Phase 3,Not Applicable
9 Antioxidants Phase 4,Phase 3,Not Applicable
10 retinol Phase 4,Phase 3,Not Applicable
11 Retinol palmitate Phase 4,Phase 3,Not Applicable
12 Vitamins Phase 4,Phase 3,Not Applicable
13 Trace Elements Phase 4,Phase 3,Not Applicable
14 Protective Agents Phase 4,Phase 3,Not Applicable
15 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Immunoglobulin G Phase 4,Phase 3
19 Adjuvants, Immunologic Phase 4
20
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
21
Pyrimethamine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 58-14-0 4993
22
Sulfadoxine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2447-57-6 17134
23
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
24
Sulfamethoxazole Approved Phase 3 723-46-6 5329
25
Tetracycline Approved, Vet_approved Phase 3,Phase 1,Phase 2 60-54-8 5353990
26
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2,Phase 1 21645-51-2
27
Dapsone Approved, Investigational Phase 2, Phase 3,Not Applicable 80-08-0 2955
28
Proguanil Approved Phase 2, Phase 3,Not Applicable 500-92-5 4923
29
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
30
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
31
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 44475014
32
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492
33
Pimecrolimus Approved, Investigational Phase 3 137071-32-0 6447131 17753757
34
Iron Approved Phase 3 7439-89-6 23925
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
36
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
37
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
38
Chlorproguanil Investigational Phase 2, Phase 3,Not Applicable 537-21-3 151170 9571037
39
Cobalamin Experimental Phase 3 13408-78-1 6438156
40 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Antiprotozoal Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
43 Fanasil, pyrimethamine drug combination Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Infective Agents, Urinary Phase 3,Phase 2,Phase 1,Not Applicable
45 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
46 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
47 Renal Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Antiparasitic Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Antimalarials Phase 3,Phase 2,Phase 1,Not Applicable
50 Folate Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 Additional Measles Vaccine at 4 Months of Age Unknown status NCT01486355 Phase 4
2 Trial of Additional Measles Vaccine to Reduce Child Mortality Unknown status NCT01644721 Phase 4
3 Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso. Unknown status NCT01668745 Phase 4
4 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Unknown status NCT01770119 Phase 4
5 The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age Unknown status NCT01306006 Phase 4
6 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
7 Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity Unknown status NCT00168623 Phase 4 Vitamin A
8 Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Unknown status NCT00168610 Phase 4 Vitamin A
9 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
10 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
11 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
12 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
13 Early Two-dose Measles Vaccination Trial Completed NCT00168558 Phase 4
14 Long-term Follow-up of Measles Antibodies Completed NCT00168571 Phase 4
15 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
16 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
17 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
18 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
19 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
20 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
21 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
22 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
23 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
24 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
25 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
26 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
27 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
28 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
29 Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
30 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
31 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
32 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
33 Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality Completed NCT00168636 Phase 4 Vitamin A
34 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
35 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4 Vivaglobin
36 Vitamin A With BCG Vaccine Completed NCT00168597 Phase 4 Vitamin A
37 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Recruiting NCT03330171 Phase 4
38 Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children Recruiting NCT03460002 Phase 4
39 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
40 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
41 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
42 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
43 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
44 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
45 MMR at 6 Months Trial Not yet recruiting NCT03780179 Phase 4
46 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
47 Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts Terminated NCT00514891 Phase 4
48 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
49 The Community Effectiveness of IPTi in Southern Tanzania Unknown status NCT00152204 Phase 3 Sulfadoxine-pyrimethamine used for IPTi;IPTi
50 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3

Search NIH Clinical Center for Measles

Cochrane evidence based reviews: measles

Genetic Tests for Measles

Anatomical Context for Measles

MalaCards organs/tissues related to Measles:

41
Brain, Eye, T Cells, Skin, Testes, B Cells, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Measles:

19
Skin

Publications for Measles

Articles related to Measles:

(show top 50) (show all 2744)
# Title Authors Year
1
A hospital-associated measles outbreak in health workers in Beijing: Implications for measles elimination in China, 2018. ( 30391419 )
2019
2
Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. ( 30478005 )
2019
3
<i>In vitro</i> measles virus infection of human lymphocyte subsets demonstrates high susceptibility and permissiveness of both naive and memory B-cells. ( 29437964 )
2018
4
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. ( 29785233 )
2018
5
Measles: what you can do. ( 29412035 )
2018
6
Absence of Measles Virus Detection from Stapes of Patients with Otosclerosis. ( 28971731 )
2018
7
Epidemiological outbreaks of measles virus in Kazakhstan during 2015. ( 29962485 )
2018
8
An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. ( 29912438 )
2018
9
Measles outbreak from February to August 2017 in Messina, Italy. ( 29938234 )
2018
10
Occurrence of measles in a country with elimination status: Amplifying measles infection in hospitalized children due to imported virus. ( 29447169 )
2018
11
Social capital, trust in health information, and acceptance of Measles-Rubella vaccination campaign in Tamil Nadu: A case-control study. ( 29943738 )
2018
12
Limitations of administrative data to identify measles cases in Ontario, Canada: a cautionary tale. ( 29981059 )
2018
13
Waning of measles maternal antibody in infants in measles elimination settings - A systematic literature review. ( 29398276 )
2018
14
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. ( 29945697 )
2018
15
Transmission potential of modified measles during an outbreak, Japan, Marcha89May 2018. ( 29921344 )
2018
16
Estimating the distribution of morbidity and mortality of childhood diarrhea, measles, and pneumonia by wealth group in low- and middle-income countries. ( 29970074 )
2018
17
Measles in Returning Adult Travelers. ( 29978780 )
2018
18
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. ( 29792776 )
2018
19
Tweeting about measles during stages of an outbreak: A semantic network approach to the framing of an emerging infectious disease. ( 29929837 )
2018
20
The neonatal anti-viral response fails to control measles virus spread in neurons despite interferon-gamma expression and a Th1-like cytokine profile. ( 29366594 )
2018
21
Public health responses during measles outbreaks in elimination settings: Strategies and challenges. ( 29932850 )
2018
22
Measles high school vaccination program, 2014-2015: online survey of parents in NSW, Australia. ( 29925088 )
2018
23
Recognizing Measles, Mumps, and Rubella in the Emergency Department. ( 29715253 )
2018
24
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
25
Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination. ( 29381765 )
2018
26
Long-term Seroprotection Rates Following One-dose Measles (9-month) and One-dose MMR Vaccination (15 months) in Indian Children. ( 29428921 )
2018
27
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7A years of age or older: a phaseA III, randomized study. ( 29902133 )
2018
28
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. ( 29792546 )
2018
29
APOBEC3G-regulated host factors interfere with measles virus replication: role of REDD1 and mTORC1 inhibition. ( 29925665 )
2018
30
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
31
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
32
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. ( 29420120 )
2018
33
Good practices and challenges in addressing poliomyelitis and measles in the European Union. ( 29659793 )
2018
34
Measles: is it still a threat? ( 29970395 )
2018
35
Measles control in Australia - threats, opportunities and future needs. ( 29934234 )
2018
36
2016 measles outbreak in Japan: A report of two cases with reappraisal of histological features. ( 29352499 )
2018
37
Vaccination strategies and results for tackling the measles outbreak in CearA! State, Brazil, 2013-2015. ( 29412346 )
2018
38
Measles vaccine in the school settings: a cross-sectional study about knowledge, personal beliefs, attitudes and practices of school teachers in northern Italy. ( 29968449 )
2018
39
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. ( 29865869 )
2018
40
50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )
2018
41
Poor quality data challenges conclusion and decision making: timely analysis of measles confirmed and suspected cases line list in Southern Nations Nationalities and People's Region, Ethiopia. ( 29433436 )
2018
42
Measles-Rubella Supplementary Immunization Activity Readiness Assessment - India, 2017-2018. ( 29975677 )
2018
43
Measles-derived vaccines to prevent emerging viral diseases. ( 29410084 )
2018
44
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
45
Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells. ( 29412740 )
2018
46
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016. ( 29965975 )
2018
47
Healthcare-associated Measles Following a Nationwide Outbreak in Mongolia. ( 29394341 )
2018
48
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. ( 29424220 )
2018
49
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
50
Revaccination with Measles-mumps-rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ( 29846533 )
2018

Variations for Measles

Expression for Measles

Search GEO for disease gene expression data for Measles.

Pathways for Measles

Pathways related to Measles according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 ADAR CD209 CD46 DDX58 DHX58 EIF2AK2
2
Show member pathways
13.54 EIF2AK2 IFNA1 IFNAR2 IFNB1 IFNG IL2
3
Show member pathways
13.38 ADAR DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1
4
Show member pathways
13.22 FCGR2B IFNG IL2 IL4 STAT1 TLR2
5
Show member pathways
13.09 DDX58 EIF2AK2 IFIH1 IFNA1 IFNAR2 IFNB1
6
Show member pathways
13.05 IFNA1 IFNAR2 IFNB1 IFNG IL2 STAT1
7
Show member pathways
13 EIF2AK2 IFNA1 IFNAR2 IFNB1 IL2 IL4
8
Show member pathways
12.89 IFNA1 IFNAR2 IFNG IL2 IL4 STAT1
9 12.85 IFNA1 IFNAR2 IFNG IL2 IL4 STAT1
10
Show member pathways
12.79 ADAR DDX58 DHX58 IFIH1 IFNA1 IFNB1
11
Show member pathways
12.6 IFNG IL2 IL4 STAT1 TLR2
12
Show member pathways
12.57 IFNA1 IFNAR2 IFNB1 IFNG IL2 IL4
13
Show member pathways
12.5 ADAR DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1
14
Show member pathways
12.45 IFNA1 IFNAR2 IFNB1 IFNG IL2 IL4
15
Show member pathways
12.34 IFNA1 IFNAR2 IFNB1 IFNG STAT1
16 12.32 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 STAT1
17
Show member pathways
12.27 ADAR IFNA1 IFNAR2 IFNB1 IFNG IL2
18
Show member pathways
12.27 ADAR CD209 CD46 DDX58 EIF2AK2 FCGR2B
19
Show member pathways
12.26 IFNG IL4 STAT1 TLR2
20
Show member pathways
12.24 IFNB1 IFNG IL4 STAT1 TLR2
21 12.23 CD209 FCGR2B IFNA1 IFNB1 IFNG STAT1
22 12.21 CD46 DDX58 DHX58 IFIH1 IFNA1 IFNG
23 12.19 IFNG STAT1 TLR2 TLR3
24
Show member pathways
12.15 EIF2AK2 IFNA1 IFNAR2 IFNB1 IFNG STAT1
25
Show member pathways
12.12 IFNG IL2 STAT1 TLR2 TLR3
26 12.11 FCGR2B IFNAR2 IFNB1 IFNG STAT1
27
Show member pathways
12.09 EIF2AK2 IFNG IL2 IL4 STAT1
28
Show member pathways
12.06 FCGR2B IFNG IL4 TLR2
29
Show member pathways
12.05 IL2 STAT1 TLR2 TLR3
30 12.05 CD209 IFNG IL2 IL4 SLAMF1
31
Show member pathways
12 IFNG IL2 IL4 STAT1
32 11.92 IFNA1 IFNAR2 IFNB1 IFNG IL2 STAT1
33 11.85 IFNG IL2 IL4 STAT1
34 11.82 CD209 IFNB1 IFNG IL2 SLAMF1
35 11.82 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 STAT1
36 11.78 IFNG IL2 IL4
37 11.78 FCGR2B IFNG IL2 IL4
38
Show member pathways
11.75 IFNG IL2 IL4
39 11.69 IFNAR2 IFNG IL2
40
Show member pathways
11.65 IFNAR2 IFNG IL2
41 11.51 IFNG IL2 IL4
42 11.45 EIF2AK2 IFNB1 IFNG STAT1
43 11.35 IFNG IL2 IL4
44 11.33 IFNB1 IFNG IL2 IL4
45 11.23 IFNG IL2 IL4
46
Show member pathways
11.02 ADAR DDX58 EIF2AK2 IFNAR2 STAT1

GO Terms for Measles

Cellular components related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CD209 IFNA1 IFNAR2 IFNB1 IFNG IL2
2 cell surface GO:0009986 9.1 CD209 CD46 MSN SLAMF1 TLR2 TLR3

Biological processes related to Measles according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.98 CD209 CD46 IFNA1 IFNB1 IFNG IL2
2 viral process GO:0016032 9.96 CD209 CD46 DDX58 DHX58 EIF2AK2 FCGR2B
3 defense response GO:0006952 9.94 FCGR2B IFNA1 IFNB1 TLR3
4 immune system process GO:0002376 9.9 ADAR CD209 CD46 DDX58 DHX58 EIF2AK2
5 viral entry into host cell GO:0046718 9.89 CD209 CD46 NECTIN4 SLAMF1
6 cellular response to interferon-gamma GO:0071346 9.88 STAT1 TLR2 TLR3
7 positive regulation of JNK cascade GO:0046330 9.87 FCGR2B SLAMF1 TLR3
8 positive regulation of inflammatory response GO:0050729 9.86 IL2 TLR2 TLR3
9 positive regulation of T cell proliferation GO:0042102 9.86 CD209 CD46 IL2 IL4
10 B cell differentiation GO:0030183 9.85 IFNA1 IFNB1 IL4
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL2 IL4
12 positive regulation of interleukin-6 production GO:0032755 9.84 DDX58 TLR2 TLR3
13 humoral immune response GO:0006959 9.83 IFNA1 IFNB1 IFNG
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 EIF2AK2 TLR2 TLR3
15 negative regulation of type I interferon production GO:0032480 9.8 DDX58 DHX58 IFIH1
16 positive regulation of interleukin-8 production GO:0032757 9.8 DDX58 TLR2 TLR3
17 response to exogenous dsRNA GO:0043330 9.8 DDX58 IFNA1 IFNB1 TLR3
18 type I interferon signaling pathway GO:0060337 9.8 ADAR IFNA1 IFNAR2 IFNB1 STAT1
19 positive regulation of interleukin-12 production GO:0032735 9.78 IFNG TLR2 TLR3
20 cellular response to interferon-beta GO:0035458 9.76 IFNB1 STAT1 TLR3
21 positive regulation of interferon-beta production GO:0032728 9.76 DDX58 IFIH1 TLR2 TLR3
22 positive regulation of chemokine production GO:0032722 9.75 EIF2AK2 TLR2 TLR3
23 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.74 IFNA1 IFNB1 IFNG
24 positive regulation of interferon-alpha production GO:0032727 9.72 DDX58 IFIH1 STAT1
25 regulation of regulatory T cell differentiation GO:0045589 9.71 IFNG IL2
26 negative regulation of phagocytosis GO:0050765 9.71 FCGR2B TLR2
27 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.71 STAT1 TLR2
28 positive regulation of tumor necrosis factor secretion GO:1904469 9.7 DDX58 IFIH1
29 regulation of innate immune response GO:0045088 9.7 DHX58 FCGR2B
30 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.7 IFNG STAT1
31 I-kappaB phosphorylation GO:0007252 9.7 TLR2 TLR3
32 response to interferon-alpha GO:0035455 9.7 ADAR EIF2AK2 IFNAR2
33 positive regulation of regulatory T cell differentiation GO:0045591 9.69 CD46 IL2
34 positive regulation of interferon-alpha secretion GO:1902741 9.68 DDX58 IFIH1
35 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL2 IL4
36 response to interferon-beta GO:0035456 9.67 IFNAR2 STAT1
37 cellular response to exogenous dsRNA GO:0071360 9.67 DDX58 IFIH1 IFNB1 TLR3
38 positive regulation of response to cytokine stimulus GO:0060760 9.65 DDX58 IFIH1
39 positive regulation of interferon-beta secretion GO:0035549 9.65 DDX58 IFIH1
40 detection of virus GO:0009597 9.65 DDX58 IFIH1 TLR3
41 positive regulation of toll-like receptor signaling pathway GO:0034123 9.64 TLR2 TLR3
42 interleukin-10 production GO:0032613 9.63 CD46 TLR2
43 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.62 DDX58 IFIH1
44 regulation of type III interferon production GO:0034344 9.61 DDX58 IFIH1
45 response to virus GO:0009615 9.61 ADAR DDX58 DHX58 EIF2AK2 IFIH1 IFNAR2
46 defense response to virus GO:0051607 9.36 ADAR DDX58 DHX58 EIF2AK2 IFIH1 IFNA1
47 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 DDX58 IFNB1 IL2 IL4 STAT1 TLR2
48 immune response GO:0006955 10.09 FCGR2B IFNG IL2 IL4 TLR2
49 regulation of signaling receptor activity GO:0010469 10.08 FCGR2B IFNA1 IFNB1 IFNG IL2 IL4
50 positive regulation of gene expression GO:0010628 10.05 CD46 DDX58 IFNG IL4 MSN TLR2

Molecular functions related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 DDX58 EIF2AK2 IFIH1 NECTIN4 SLAMF1 STAT1
2 signaling receptor activity GO:0038023 9.72 CD46 NECTIN4 SLAMF1 TLR2 TLR3
3 single-stranded RNA binding GO:0003727 9.61 DDX58 DHX58 IFIH1
4 cytokine activity GO:0005125 9.55 IFNA1 IFNB1 IFNG IL2 IL4
5 cytokine receptor binding GO:0005126 9.54 IFNA1 IFNB1 IL4
6 type I interferon receptor binding GO:0005132 9.46 IFNA1 IFNB1
7 virus receptor activity GO:0001618 9.26 CD209 CD46 NECTIN4 SLAMF1
8 double-stranded RNA binding GO:0003725 9.17 ADAR DDX58 DHX58 EIF2AK2 IFIH1 MSN
9 protein binding GO:0005515 10.36 ADAR CD209 CD46 DDX58 DHX58 EIF2AK2

Sources for Measles

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....